Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...

What a Quinn Hughes Deal Could Really Mean for the Flyers

If a report surfaces linking an NHL team to Quinn Hughes, the first reaction is usually some version of: well, of course they ...

Shane Neilson's latest poetry collection is 'aggressively weird'

The Canadian poet and author talks to CBC Books about The Reign, a poetry collection that tells a novel-in-verse tale set ...